Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MM Label Debated As FDA Word Nears On Velcade

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval that includes transplant-eligible patients might not matter much, analyst says.

You may also be interested in...



Velcade Wins FDA Clearance In First-Line MM

Agency hits PDUFA date with “quite broad” new label, exec tells “The Pink Sheet” DAILY.

Velcade Wins FDA Clearance In First-Line MM

Agency hits PDUFA date with “quite broad” new label, exec tells “The Pink Sheet” DAILY.

Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition

Japanese drug maker takes a stronger position in oncology, expands U.S. presence.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel